trial, their I moment team study, enabling hidradenitis they've us on fully to work morning, want to execution today's Doug, the recent on to you also everybody. of also a analyze and to the all the commend weeks from you, the thus the Thank but suppurativa done of tremendous with Aclaris in provide results take good overview.
of Directing our pipeline. you four, slide summary to the development
progress dose the asset multiple the on ascending X in Phase ATI-XXXX Building to ascending our ATI-XXXX study. study and with dose volunteers well. healthy start continues single of The successes ITK/JAKX inhibitor. clinical stage Let's
and year. second are We on very track have this the in pharmacokinetics, pharmacodynamics much to half of safety results
is announced, previously be to first a population we clinical Xa in patient in ATI-XXXX of study a colitis. As proof-of-concept our ulcerative Phase trial planned
X dose of a of quickly to the in you study. with this results completion provide ulcerative after can that Phase more details Later study. study we fully colitis will and be year, initiate we ascending is the well have position this design finalized upon planning on we proof-of-concept the The multiple ongoing underway so have the
to MKX academic our on of setting next-generation ATI-XXXX, in breast prospective Moving and objective in closer moving to with ATI-XXXX ultimate cancer partners cancer. into metastatic inhibitor, our the get pancreatic we're
Now shifting to slide six.
our in exposure, ATI-XXXX, was JAKX/X follow-up and for Phase systemic designed For topical inhibitor, dermatitis a our a minimize study. Phase are which as Xb atopic skin to conducting Xa efficacy successful we study
limited are The Xa Phase further and efficacy seen exposure the evaluate validate objectives of the safety trial and ATI-XXXX the the systemic in to of study.
which the X% regimen lower several studied well that twice dose trial in once several strains and Phase will are formulation and the development. daily Phase We progressing best Xa for twice-daily also dose we studying X including dose as be so into assessing strains, applications know as
a children Index patients. XX, of meaningful with We from been primary therapies also The the children. is other target given this of the medical at to week percentage array and Severity and four. of include baseline Eczema expanded or recently endpoint The age Area We've (EASI) in score our to importance disease the population some study down need in in change the the the topical enrollment very study milder in seen by XXX is in broader success trial patients encouraged patients.
want in mild past conducting is this in not and As protocol winter patients assure evaluate season eastern protocol meaningfully patients of as other some from such, enroll severe because atopic locations, dermatitis, many important This we encountered the you may And portions enrollment some mild we driven we in companies of winter well. some southern recently trials the have dermatitis, US. challenges, them. adequate particularly just particularly seen modification the but reported to include as to moderate have and extended by atopic to the mild can also
associated few amendment, atopic In dryness the cold we Since weather which just heating in meaningful effect winter into protocol can have and increase weeks already went a first of with the seen dermatitis. screening. exacerbate this
are terms that half we to guidance learn guidance results and in prior the move of about protocol. to our as amended year, we line We will continue of of our updating top from of the to up midyear tighten impact timing this of second more guidance
seven. slide to Moving
statistically efficacy and trends of itch, secondary percent primary analysis by positive our and a of ATI-XXXX of area reminder, improvements achieved IGA modified EASI-XX in reduction including As body results in in endpoints, Phase impacted at four, the week significant observed responder were endpoint trial, surface disease. Xa responders, the
Shifting to eight. slide
have of ATI-XXXX JAKX/X, patients Importantly, than a the low to never safety seen of patients ICXX ATI-XXXX because was average with observed of the topical following X/XX soft in greater greater levels the and plasma profile and the had than application approach, three the tolerability X% of topical ICXX. only of concentrations were concentrations favorable very and
more a of with trial full set. that have we onto Now HS We'll begin moving ATI-XXX. the overview the comprehensive data now
not know reported our either all in endpoints or top that results HS. in ATI-XXX the from you did As fit line we March, secondary primary efficacy
As placebo on the the treatment. placebo slide patients arm the and randomized complete ATI-XXX. patients XX on XX we shown active on on into and XX, with with study Overall, XX XX study XX on
the As which unusually buckets, These trial our demonstrate can efficacy by on overall. the previously ATI-XXX of pharmacodynamics. from be into noted, today will modest fall ATI-XXX was applied detail the discuss spend safety this for HS. the study the overshadowed pharmacodynamics. Joe then elements want of safety did in to in and not majority will two large to that I saw time and do effect. an effect, of I elements understanding primarily placebo a elements discuss our We the treatment
steady the Slide baseline XX shows characteristics. demographics and
very From a serious on slide infections. with had organ patient and We we trial no toxicities safety of enrolled XX, serious no that opportunistic on perspective, more or proud inclusion representative we HS people. underrepresented was historically are events quite adverse ATI-XXX, of that no real-world end a serious populations
arm a What from we discontinued early have the starting given shown high enrollment slide early was from And patients in placebo this increase is of did XX. saw active we discontinuation of Difficulty] trial meaningful made Overall, treatment decision the reason of the efficacy the on treatment. we fall. and observation number arm the and unsurprisingly, XX [Technical the to see, discontinuations the study in last days we lack primary
to discontinuations loss of adverse and arm four balanced the XX due between the ATI-XXX and investigator the relatively with an and withdrawings noted event, arm. of efficacy The for divergence lack to from stated follow-up, in and were arms. placebo-treated due withdrawals placebo the ATI-XXX Withdrawals to withdrawal was consent,
however, than no active study. to at AN bit XX not treatment-related the the a deeper, seeing we talk seven event, count majority efficacy. Their noted patients either of worse or the due was the the we better of that arm of were withdrew adverse who in start When an
not are events the to who adverse continue a intensity, it discontinuation seeing to not treatment benefit in of of had moderate a incentive that most surprising treatment. only While leading little were is patients
Further, which or most discontinuation closely like new events subcutaneous growing that worsening worsening HS HS. to to is the related acne, to adverse led were commonly abscess related abscess,
a when typically resolves also investigator investigators in arthritis continue for the known topic, phenomenon no to which some course, We discontinuations the further this saw trials. few of with period is we treatment in and occurs arthritis a this we had this also withdraw subjects dizziness, headache ongoing And rheumatoid due patients further or psoriatic early education to And reason. and that provided treatment. even patients on for education
quite the important to we process, in trial. when our into seeing are stage trial and initiated and arthritis we that an to well current the model advanced discontinuation enrollment of trial, a our we is rheumatoid below rate our projections It's pertaining stable note are
let's which the CK, or from attention captured to is elevations shown line the Now that creatine in on on topic results, XX. other slide phosphokinase move top
we the learned brings of patients CK had was study one we percentage release, such, that that reported five or data, reported. XX.X% patient to below drug, that has prior CK category, as were so event. these receiving elevated not we threshold noted our press XX% down elevated the been level. this which adverse our that Subsequent top issued we treatment-emergent we finalized line, had And from treatment-emergent blood a their patients removed to there of that When events as that
X during covered CK and of patients both some patients elevations elevations, majority with study. reported were you and drug, were in the also however, we on ATI-XXX Overall, placebo these modest of Grade two The placebo in CK ATI-XXX. drawers as Grade were on X, elevations Grade CK point Six with three on though, these on had see XX and study elevation. laboratory levels can one XX X on in of
even transient and most moving patients and when most typically to However, were the treatment-emergent elevations where typically to return XX, CK baseline that Grade treatment. continued slide X above on
of history them a were with Many exercise. associated of
were associated were associated more something with. is events There elevations was no severe would More on. not suggest adverse going that CK importantly what the
were example, We skeletal CK inhibitors For that muscle have no with abnormalities not CK do effective kidney from the inhibitors. weakness, or like benign know TNF been that and treatments pain, other elevations reported elevations seen source. muscle anti-inflammatory JAK
Overall current The transient CK profile slide see do meaningful or kidney patients elevations or XX. We've development. serious in symptoms. be seen stage cytopenias that not very we seen safety with and the continued profile muscle-related to to We've no Moving to no with the event are we effects expected. through and adverse as have disappear opportunistic some any or generally on treatment infections. with has ATI-XXX clinical pleased continued of date, liver
have in and are no now identified. chronic to Lastly, issues concern note the completed we of all it there is with our pathology of X, preparation results for studies Phase toxicology available, important that
I'd to pharmacodynamic that over Joe? HS call to the turn pharmacokinetic to discuss study. from findings With the the like Joe and
